This protocol addresses patients with unresectable, inoperable, or metastatic giant cell tumor of bone who are pregnant. The standard systemic agent for this condition is contraindicated in pregnancy, creating a specific therapeutic challenge that requires an alternative approach.
Denosumab is contraindicated for pregnant patients. A different systemic strategy must be considered to safely manage advanced giant cell tumor of bone throughout pregnancy.
An alternative biologic agent — one not contraindicated in pregnancy and associated with a distinct adverse-effect profile — has been identified as a potential option in this setting. The complete regimen, selection criteria, and clinical algorithm are available in the full protocol.
Treatment aims to achieve ossification, new bone formation, and remodeling at the tumor site.
DOI: 10.3390/curroncol31040157